Focus on select generics has rewarded Ajanta Pharma with healthy margins whereas entry into the regulated markets of US and EU is likely to be the key growth driver for the company. Ajanta also operates a US FDA approved manufacturing facility at Aurangabad. A debt equity ratio of 0.6 will support its ambitious capex plans of Rs 390 crore in the next two years and the management expects to add Rs 1,000 crore to its topline by FY15.
Ajanta Pharma’s entry into the US & EU markets is likely to be its key growth driver…
By Research Desk | Aug 23, 2012